table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2028)
1.4.2 East Asia Market States and Outlook (2023-2028)
1.4.3 Europe Market States and Outlook (2023-2028)
1.4.4 South Asia Market States and Outlook (2023-2028)
1.4.5 Southeast Asia Market States and Outlook (2023-2028)
1.4.6 Middle East Market States and Outlook (2023-2028)
1.4.7 Africa Market States and Outlook (2023-2028)
1.4.8 Oceania Market States and Outlook (2023-2028)
1.4.9 South America Market States and Outlook (2023-2028)
1.5 Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Analysis from 2023 to 2028
1.5.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Analysis from 2023 to 2028 by Consumption Volume
1.5.2 Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Analysis from 2023 to 2028 by Value
1.5.3 Global Antisense Oligonucleotide (ASO) Therapeutics Price Trends Analysis from 2023 to 2028
1.6 COVID-19 Outbreak: Antisense Oligonucleotide (ASO) Therapeutics Industry Impact
Chapter 2 Global Antisense Oligonucleotide (ASO) Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Antisense Oligonucleotide (ASO) Therapeutics (Volume and Value) by Type
2.1.1 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption and Market Share by Type (2017-2022)
2.1.2 Global Antisense Oligonucleotide (ASO) Therapeutics Revenue and Market Share by Type (2017-2022)
2.2 Global Antisense Oligonucleotide (ASO) Therapeutics (Volume and Value) by Application
2.2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption and Market Share by Application (2017-2022)
2.2.2 Global Antisense Oligonucleotide (ASO) Therapeutics Revenue and Market Share by Application (2017-2022)
2.3 Global Antisense Oligonucleotide (ASO) Therapeutics (Volume and Value) by Regions
2.3.1 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Antisense Oligonucleotide (ASO) Therapeutics Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Antisense Oligonucleotide (ASO) Therapeutics Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption by Regions (2017-2022)
4.2 North America Antisense Oligonucleotide (ASO) Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Antisense Oligonucleotide (ASO) Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Antisense Oligonucleotide (ASO) Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Antisense Oligonucleotide (ASO) Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Antisense Oligonucleotide (ASO) Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Antisense Oligonucleotide (ASO) Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Antisense Oligonucleotide (ASO) Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.10 South America Antisense Oligonucleotide (ASO) Therapeutics Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
5.1 North America Antisense Oligonucleotide (ASO) Therapeutics Consumption and Value Analysis
5.1.1 North America Antisense Oligonucleotide (ASO) Therapeutics Market Under COVID-19
5.2 North America Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume by Types
5.3 North America Antisense Oligonucleotide (ASO) Therapeutics Consumption Structure by Application
5.4 North America Antisense Oligonucleotide (ASO) Therapeutics Consumption by Top Countries
5.4.1 United States Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
5.4.2 Canada Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
5.4.3 Mexico Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
Chapter 6 East Asia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
6.1 East Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption and Value Analysis
6.1.1 East Asia Antisense Oligonucleotide (ASO) Therapeutics Market Under COVID-19
6.2 East Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume by Types
6.3 East Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption Structure by Application
6.4 East Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption by Top Countries
6.4.1 China Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
6.4.2 Japan Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
6.4.3 South Korea Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
Chapter 7 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
7.1 Europe Antisense Oligonucleotide (ASO) Therapeutics Consumption and Value Analysis
7.1.1 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Under COVID-19
7.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume by Types
7.3 Europe Antisense Oligonucleotide (ASO) Therapeutics Consumption Structure by Application
7.4 Europe Antisense Oligonucleotide (ASO) Therapeutics Consumption by Top Countries
7.4.1 Germany Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
7.4.2 UK Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
7.4.3 France Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
7.4.4 Italy Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
7.4.5 Russia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
7.4.6 Spain Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
7.4.7 Netherlands Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
7.4.8 Switzerland Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
7.4.9 Poland Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
Chapter 8 South Asia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
8.1 South Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption and Value Analysis
8.1.1 South Asia Antisense Oligonucleotide (ASO) Therapeutics Market Under COVID-19
8.2 South Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume by Types
8.3 South Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption Structure by Application
8.4 South Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption by Top Countries
8.4.1 India Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
8.4.2 Pakistan Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
9.1 Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption and Value Analysis
9.1.1 Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Market Under COVID-19
9.2 Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume by Types
9.3 Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption Structure by Application
9.4 Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption by Top Countries
9.4.1 Indonesia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
9.4.2 Thailand Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
9.4.3 Singapore Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
9.4.4 Malaysia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
9.4.5 Philippines Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
9.4.6 Vietnam Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
9.4.7 Myanmar Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
Chapter 10 Middle East Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
10.1 Middle East Antisense Oligonucleotide (ASO) Therapeutics Consumption and Value Analysis
10.1.1 Middle East Antisense Oligonucleotide (ASO) Therapeutics Market Under COVID-19
10.2 Middle East Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume by Types
10.3 Middle East Antisense Oligonucleotide (ASO) Therapeutics Consumption Structure by Application
10.4 Middle East Antisense Oligonucleotide (ASO) Therapeutics Consumption by Top Countries
10.4.1 Turkey Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
10.4.3 Iran Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
10.4.5 Israel Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
10.4.6 Iraq Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
10.4.7 Qatar Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
10.4.8 Kuwait Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
10.4.9 Oman Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
Chapter 11 Africa Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
11.1 Africa Antisense Oligonucleotide (ASO) Therapeutics Consumption and Value Analysis
11.1.1 Africa Antisense Oligonucleotide (ASO) Therapeutics Market Under COVID-19
11.2 Africa Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume by Types
11.3 Africa Antisense Oligonucleotide (ASO) Therapeutics Consumption Structure by Application
11.4 Africa Antisense Oligonucleotide (ASO) Therapeutics Consumption by Top Countries
11.4.1 Nigeria Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
11.4.2 South Africa Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
11.4.3 Egypt Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
11.4.4 Algeria Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
11.4.5 Morocco Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
Chapter 12 Oceania Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
12.1 Oceania Antisense Oligonucleotide (ASO) Therapeutics Consumption and Value Analysis
12.2 Oceania Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume by Types
12.3 Oceania Antisense Oligonucleotide (ASO) Therapeutics Consumption Structure by Application
12.4 Oceania Antisense Oligonucleotide (ASO) Therapeutics Consumption by Top Countries
12.4.1 Australia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
12.4.2 New Zealand Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
Chapter 13 South America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
13.1 South America Antisense Oligonucleotide (ASO) Therapeutics Consumption and Value Analysis
13.1.1 South America Antisense Oligonucleotide (ASO) Therapeutics Market Under COVID-19
13.2 South America Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume by Types
13.3 South America Antisense Oligonucleotide (ASO) Therapeutics Consumption Structure by Application
13.4 South America Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume by Major Countries
13.4.1 Brazil Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
13.4.2 Argentina Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
13.4.3 Columbia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
13.4.4 Chile Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
13.4.5 Venezuela Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
13.4.6 Peru Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
13.4.8 Ecuador Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Antisense Oligonucleotide (ASO) Therapeutics Business
14.1 Ionis Pharmaceuticals, Inc
14.1.1 Ionis Pharmaceuticals, Inc Company Profile
14.1.2 Ionis Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Product Specification
14.1.3 Ionis Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Sarpeta Therapeutics Inc.
14.2.1 Sarpeta Therapeutics Inc. Company Profile
14.2.2 Sarpeta Therapeutics Inc. Antisense Oligonucleotide (ASO) Therapeutics Product Specification
14.2.3 Sarpeta Therapeutics Inc. Antisense Oligonucleotide (ASO) Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Biogen Inc
14.3.1 Biogen Inc Company Profile
14.3.2 Biogen Inc Antisense Oligonucleotide (ASO) Therapeutics Product Specification
14.3.3 Biogen Inc Antisense Oligonucleotide (ASO) Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 Alnylam Pharmaceuticals, Inc
14.4.1 Alnylam Pharmaceuticals, Inc Company Profile
14.4.2 Alnylam Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Product Specification
14.4.3 Alnylam Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Antisense Therapeutics Limited
14.5.1 Antisense Therapeutics Limited Company Profile
14.5.2 Antisense Therapeutics Limited Antisense Oligonucleotide (ASO) Therapeutics Product Specification
14.5.3 Antisense Therapeutics Limited Antisense Oligonucleotide (ASO) Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Arrowhead Pharmaceuticals Inc.
14.6.1 Arrowhead Pharmaceuticals Inc. Company Profile
14.6.2 Arrowhead Pharmaceuticals Inc. Antisense Oligonucleotide (ASO) Therapeutics Product Specification
14.6.3 Arrowhead Pharmaceuticals Inc. Antisense Oligonucleotide (ASO) Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 Enzon Pharmaceuticals, Inc.
14.7.1 Enzon Pharmaceuticals, Inc. Company Profile
14.7.2 Enzon Pharmaceuticals, Inc. Antisense Oligonucleotide (ASO) Therapeutics Product Specification
14.7.3 Enzon Pharmaceuticals, Inc. Antisense Oligonucleotide (ASO) Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 Bio-Path Holdings, Inc.
14.8.1 Bio-Path Holdings, Inc. Company Profile
14.8.2 Bio-Path Holdings, Inc. Antisense Oligonucleotide (ASO) Therapeutics Product Specification
14.8.3 Bio-Path Holdings, Inc. Antisense Oligonucleotide (ASO) Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 GlaxoSmithKline PLC
14.9.1 GlaxoSmithKline PLC Company Profile
14.9.2 GlaxoSmithKline PLC Antisense Oligonucleotide (ASO) Therapeutics Product Specification
14.9.3 GlaxoSmithKline PLC Antisense Oligonucleotide (ASO) Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Geron Corporation (Geron)
14.10.1 Geron Corporation (Geron) Company Profile
14.10.2 Geron Corporation (Geron) Antisense Oligonucleotide (ASO) Therapeutics Product Specification
14.10.3 Geron Corporation (Geron) Antisense Oligonucleotide (ASO) Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Antisense Oligonucleotide (ASO) Therapeutics Market Forecast (2023-2028)
15.1 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Price Forecast (2023-2028)
15.1.1 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume and Growth Rate Forecast (2023-2028)
15.1.2 Global Antisense Oligonucleotide (ASO) Therapeutics Value and Growth Rate Forecast (2023-2028)
15.2 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Value and Growth Rate Forecast by Region (2023-2028)
15.2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume and Growth Rate Forecast by Regions (2023-2028)
15.2.2 Global Antisense Oligonucleotide (ASO) Therapeutics Value and Growth Rate Forecast by Regions (2023-2028)
15.2.3 North America Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.4 East Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.5 Europe Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.6 South Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.7 Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.8 Middle East Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.9 Africa Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.10 Oceania Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.11 South America Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.3 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume, Revenue and Price Forecast by Type (2023-2028)
15.3.1 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption Forecast by Type (2023-2028)
15.3.2 Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Forecast by Type (2023-2028)
15.3.3 Global Antisense Oligonucleotide (ASO) Therapeutics Price Forecast by Type (2023-2028)
15.4 Global Antisense Oligonucleotide (ASO) Therapeutics Consumption Volume Forecast by Application (2023-2028)
15.5 Antisense Oligonucleotide (ASO) Therapeutics Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
